Lilly Mounjaro Outperforms Rivals in Early Diabetes Study
Tirzepatide showed superior blood sugar control in early type 2 diabetes patients. New research also linked long COVID symptoms to harmful autoantibodies.
Xurve View
Insights:
Xurve View
Eli Lilly reported that 60% of patients using tirzepatide achieved normal blood sugar levels compared to 24% using standard GLP-1 therapies. The SURPASS-EARLY trial, funded by Lilly, tracked nearly 800 adults with type 2 diabetes over two years.
